Pharming Group N.V. (PHAR) Long-Term Investments (2019 - 2023)

Pharming (PHAR) has disclosed Long-Term Investments for 5 consecutive years, with $2.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Long-Term Investments rose 401.24% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2023, up 401.24%, and an annual FY2023 reading of $2.0 million, up 401.24% over the prior year.
  • Long-Term Investments was $2.0 million for Q4 2023 at Pharming, up from $403000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $6.9 million in Q4 2020 and bottomed at $403000.0 in Q4 2022.
  • Average Long-Term Investments over 5 years is $3.4 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Long-Term Investments tumbled 79.03% in 2021, then surged 401.24% in 2023.
  • Year by year, Long-Term Investments stood at $6.1 million in 2019, then rose by 13.35% to $6.9 million in 2020, then crashed by 79.03% to $1.4 million in 2021, then plummeted by 72.19% to $403000.0 in 2022, then soared by 401.24% to $2.0 million in 2023.
  • Business Quant data shows Long-Term Investments for PHAR at $2.0 million in Q4 2023, $403000.0 in Q4 2022, and $1.4 million in Q4 2021.